In a meta-analysis of 48 trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting its use in clinical trials. https://www.nature.com/articles/s41591-025-04057-z

Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks even in data-scarce scenarios, such as rare cancer diagnosis. https://www.nature.com/articles/s41591-025-03982-3

News & Views: A study expands the utility of gold-standard models to assess risks linked to consuming raw milk and cheese contaminated with #influenzaA — marking an important step toward better risk assessments in #publichealth. https://www.nature.com/articles/s41591-025-04020-y

In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety profiles and resulted in durable virologic suppression. https://www.nature.com/articles/s41591-025-04041-7

In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline https://www.nature.com/articles/s41591-025-03955-6 @WendyYau01 @HarvardAging @MGHNeurology

The first-in-human trial of AB-1002 suggests a cautious return of #cardiac #genetherapy after earlier setbacks, with a new target, dose optimization & improved vector design shaping future directions. News & Views from Oliver Müller & colleagues https://www.nature.com/articles/s41591-025-04002-0

⭐Research highlight: Creativity enhances #brainhealth by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies. Nature Communications#brainhealthhttps://www.nature.com/articles/d41591-025-00063-3

⭐Research highlight: Baby wraps treated with the insecticide permethrin reduced the incidence of #malaria in infants by 66%, according to a randomized controlled trial in Uganda. @NEJM https://www.nature.com/articles/d41591-025-00061-5#malaria

Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w

Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3#ESMO25

Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w

Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y

Now at #ESMO25: in the phase 3 RELATIVITY-098 trial, nivolumab + relatlimab did not significantly change recurrence free survival for patients with stage III/IV resected melanoma, and the absence of tumor infiltrating LAG3+ T cells may play a role. https://www.nature.com/articles/s41591-025-04032-8#ESMO25

A new study provides physiological insights into the dying process, which could have substantial implications for resuscitation science, death determination and organ donation. Read the News & Views from Michael Rubin and Matthew Kirschen https://www.nature.com/articles/s41591-025-03941-y

Lots of great AI content in Nature Medicine: 🧠 Tina Hernandez-Boussard explores the "fragile intelligence" of ChatGPT 🩺 Our editorial calls for stronger support for the human in the loop to ensure trustworthy AI in healthcare 🔗 Fragile Intelligence 🔗 Trustworthy AI #AIinMedicine #NatureMedicine

Three studies that leverage blood-based gene expression data identify host response signatures in #sepsis and critical illnesses, opening a pathway to mechanism-anchored #precisiontherapy. News & Views from Robert Stevens and Carl Harris @jhu.edu https://www.nature.com/articles/s41591-025-04005-x#sepsis

Two phase 1 studies show promising outcomes with #CARTcell therapies in systemic #lupus erythematosus, but the next stage of development must address pitfalls around comparator arms & ancillary treatments News & Views from Joan Merill & Judith James https://www.nature.com/articles/s41591-025-03987-y

A clinical trial of pregnant women provides critical safety and immunogenicity data in support of a two-dose #Ebola #vaccine; similar research is urgently needed for other diseases. News & Views from Beate Kampmann, Alice Hucko @ChariteBerlin https://www.nature.com/articles/s41591-025-04000-2

#GenerativeAI in #medicine: Our latest Review summarizes recent technical advancements, outlines how new models might improve #healthcare, and discusses validation approaches. @dukenus @DanielTing20 @drnigam @curtlanglotz https://www.nature.com/articles/s41591-025-03983-2#GenerativeAI

📢 New in Nature Medicine: “The damage done” examines the global fallout from the 2025 NIH funding cuts—impacting trials, patients, and decades of research. Huge thanks to all the contributors who were able to share their stories. 🔗 Read here

A phase 3 trial found that VER-01, a full-spectrum #cannabis extract, reduces chronic low #BackPain, improves function and sleep, and shows no signs of dependence or withdrawal. #ChronicPain, #LowBackPain #ChronicPainRelief #PainRelief https://www.nature.com/articles/s41591-025-03977-0

🩸Two new papers out today in @natmed.nature.com on #Sepsis. www.nature.com/articles/s41... www.nature.com/articles/s41...

NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...

As Nature Medicine celebrates the 30th anniversary of its launch, we reflect on what the future holds for medicine and for our journal. In this Series, we spotlight key challenges and opportunities as we look to the next 30 years of biomedical innovation.